Sunshine Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023; financial statements are unaudited. Sunshine Biopharma develops proprietary drug candidates and, through Canadian subsidiaries, sells generic prescription and over-the-counter products. Nora Pharma, acquired in October 2022, operates a portfolio of 51 marketed generic drugs; 32 more are scheduled for launch in 2024–2025.
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $5.96 million | $0.13 million | $16.41 million | $0.41 million |
| Gross profit / margin | $1.99 million / 33.4% | $0.07 million / 50.5% | $5.77 million / 35.2% | $0.21 million / 50.6% |
| Operating loss | $0.78 million | $1.72 million | $3.60 million | $3.64 million |
| Net loss | $0.65 million | $1.46 million | $3.26 million | $3.23 million |
| Net loss per share | $0.04 | $0.08 | $0.133 in financial statements | $0.26 |
Cash flow and liquidity: Cash and equivalents were $18.85 million at September 30, 2023, down from $21.83 million at December 31, 2022. Nine-month operating cash use was $6.09 million; investing cash use was $0.39 million; financing provided $3.46 million. Current assets were $25.43 million and current liabilities $5.09 million. Total liabilities were $5.69 million, including a $2.55 million current earnout payable and $0.67 million in lease liabilities. The filing reports no notes payable at period end.
Changes and business developments
- Revenue growth primarily reflects Nora Pharma, whose results were not included in the prior-year comparison. The company attributed the lower gross margin to higher manufacturing costs for generic drugs.
- Nine-month G&A rose to $9.37 million from $3.84 million, driven especially by salaries, office costs, consulting and higher operating overhead. The operating loss was slightly lower, while the net loss was slightly higher year over year.
- The company raised $4.09 million net in a May 2023 private placement. Common shares outstanding increased to 25,678,290 at September 30, 2023 from 22,585,632 at year-end 2022. Warrants issued in financings create potential dilution.
- The company paid $1.08 million toward the Nora Pharma acquisition earnout during the nine months; $2.55 million remained payable at quarter-end.
Outlook, risks and unusual items
- Management estimates existing cash will fund operations for 18–24 months, but says revenue is not sufficient to fully implement its business plan. It estimates approximately $30 million of additional capital would be needed for expanded drug development and generic operations, potentially including a Phase I trial. No committed financing arrangements are disclosed, and future funding may not be available on acceptable terms.
- Adva-27a IND-enabling studies were paused after unfavorable laboratory results. On November 2, 2023, the company gave notice to terminate its research agreement, effective December 2, while it reviews possible chemical modification of the compound.
- On October 18, 2023, the company amended its Tradeable Warrant agreement to reduce the exercise price to $0.11 and restore the CEO’s voting rights under Series B preferred stock. These were subsequent events, after quarter-end.
- Updated Canadian generic-drug prices took effect October 1, 2023 under an industry agreement; pricing is subject to government and reimbursement policies. Management identifies these as factors that can affect generic-drug pricing.
- No formal revenue or earnings guidance is provided. Management’s product pipeline includes 32 generic drugs scheduled for 2024–2025 and proprietary candidates K1.1 and SBFM-PL4 at preclinical stages. Management said it anticipated beginning K1.1 mouse studies later in 2023.
- Management assessed disclosure controls as effective at reasonable assurance levels; it reported no material legal proceedings and no off-balance-sheet arrangements.
Investor verification points
- Reconcile nine-month loss per share: the financial statements report $0.133, while MD&A states $0.12.
- Track operating cash use, the 18–24-month cash runway estimate, and the feasibility and terms of the stated additional capital need.
- Verify launch timing, regulatory progress and commercial contribution of the 32 planned generic products, alongside the effect of updated Canadian pricing.
- Assess potential dilution from outstanding warrants, including the May 2023 warrants and the subsequent Tradeable Warrant repricing.
- Monitor Adva-27a’s paused development and any decision to modify or discontinue the program.